NO20020214D0 - Substituerte oksozaheterocyklylforbindelser - Google Patents
Substituerte oksozaheterocyklylforbindelserInfo
- Publication number
- NO20020214D0 NO20020214D0 NO20020214A NO20020214A NO20020214D0 NO 20020214 D0 NO20020214 D0 NO 20020214D0 NO 20020214 A NO20020214 A NO 20020214A NO 20020214 A NO20020214 A NO 20020214A NO 20020214 D0 NO20020214 D0 NO 20020214D0
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- factor
- oxozaheterocyclyl
- substituted
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Dental Preparations (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36319699A | 1999-07-28 | 1999-07-28 | |
PCT/IB2000/001156 WO2001007436A2 (en) | 1999-07-28 | 2000-07-26 | Substituted oxoazaheterocyclyl compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20020214D0 true NO20020214D0 (no) | 2002-01-15 |
NO20020214L NO20020214L (no) | 2002-04-02 |
Family
ID=23429232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020214A NO20020214L (no) | 1999-07-28 | 2002-01-15 | Substituerte oksoazaheterocyklylforbindelser |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1208097B1 (no) |
JP (1) | JP4829449B2 (no) |
KR (1) | KR20020087041A (no) |
CN (1) | CN1420882A (no) |
AT (1) | ATE423113T1 (no) |
AU (1) | AU773227B2 (no) |
BG (1) | BG106340A (no) |
BR (1) | BR0013179A (no) |
CA (1) | CA2382755A1 (no) |
CR (1) | CR6563A (no) |
CZ (1) | CZ2002323A3 (no) |
DE (1) | DE60041584D1 (no) |
EE (1) | EE200200045A (no) |
HK (1) | HK1054227A1 (no) |
HR (1) | HRP20020076A2 (no) |
HU (1) | HUP0203375A3 (no) |
IL (2) | IL147495A0 (no) |
MX (1) | MXPA02000888A (no) |
NO (1) | NO20020214L (no) |
PL (1) | PL354998A1 (no) |
RU (1) | RU2002105011A (no) |
SK (1) | SK1182002A3 (no) |
TR (1) | TR200200225T2 (no) |
WO (1) | WO2001007436A2 (no) |
ZA (1) | ZA200200543B (no) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ520588A (en) | 2000-03-21 | 2004-06-25 | Smithkline Beecham Corp | Protease inhibitors |
BR0107282A (pt) * | 2000-09-29 | 2004-07-06 | Cor Therapeutics Inc | Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas |
EP1363705B9 (en) * | 2001-02-02 | 2012-11-07 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
NZ530202A (en) | 2001-07-02 | 2005-06-24 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
JP2005504771A (ja) * | 2001-08-24 | 2005-02-17 | エール ユニヴァーシティ | 抗腫瘍・抗癌剤としてのピペラジノン化合物と処置方法 |
AU2007229363B2 (en) * | 2001-08-24 | 2009-06-04 | University Of South Florida | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment |
GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
US7087604B2 (en) | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
JP4429738B2 (ja) | 2002-04-25 | 2010-03-10 | 帝人株式会社 | Ccr3拮抗作用を有する4,4−二置換ピペリジン誘導体 |
AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
AU2003272972A1 (en) * | 2002-10-11 | 2004-05-04 | Kowa Co., Ltd. | Method of treatment for cancer |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
CN1745064A (zh) | 2002-12-06 | 2006-03-08 | 泊达研究基金会 | 用于治疗受损的哺乳动物神经组织的吡啶 |
US8729107B2 (en) | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
RU2333200C2 (ru) | 2003-03-07 | 2008-09-10 | Астеллас Фарма Инк. | Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил |
SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
WO2006019497A2 (en) | 2004-06-17 | 2006-02-23 | Neurocrine Biosciences, Inc. | Sleep-inducing compounds and methods related thereto |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
KR101063663B1 (ko) | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 |
WO2007008144A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
US20080200431A1 (en) * | 2005-07-08 | 2008-08-21 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
US8314127B2 (en) | 2005-07-21 | 2012-11-20 | Astrazeneca Ab | Piperidine derivatives |
EP1932839A4 (en) * | 2005-09-06 | 2014-09-10 | Shionogi & Co | INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
ES2625378T3 (es) | 2005-09-27 | 2017-07-19 | Shionogi & Co., Ltd. | Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2 |
AU2006332945C1 (en) | 2005-12-23 | 2013-02-28 | Wyeth | Modified lysine-mimetic compounds |
EP1988077A4 (en) * | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
WO2007118130A2 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Antibacterial agents |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
EP2026654A4 (en) * | 2006-05-26 | 2013-07-17 | Univ Louisville Res Found | MACROPHAGE MIGRATION HEMMFAKTOR ANTAGONISTS AND USE METHOD THEREFOR |
EP1882688A1 (en) | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
EP2074087A2 (en) | 2006-12-21 | 2009-07-01 | Wyeth | Synthesis of pyrrolidine compounds |
KR101313804B1 (ko) * | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Hsp90 억제제로서의 융합된 아미노 피리딘 |
WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
ES2666324T3 (es) | 2008-10-28 | 2018-05-04 | Arena Pharmaceuticals, Inc. | Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo |
EP2480235A4 (en) | 2009-09-24 | 2013-05-08 | Univ Louisville Res Found | NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR |
US9155790B2 (en) | 2010-05-20 | 2015-10-13 | University of Lousiville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
KR101251282B1 (ko) | 2010-10-18 | 2013-04-10 | 서울대학교산학협력단 | 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물 |
CN102552274B (zh) * | 2010-11-12 | 2013-10-23 | 姚雪彪 | 动点马达蛋白小分子抑制剂在抑制肿瘤细胞增殖中的应用 |
US8980924B2 (en) | 2010-11-24 | 2015-03-17 | The Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease |
PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
WO2015168286A1 (en) | 2014-04-30 | 2015-11-05 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparaiton and use |
AU2015295287B2 (en) | 2014-07-31 | 2019-07-04 | Basf Se | Process for preparing pyrazoles |
CN104672235B (zh) * | 2015-02-14 | 2016-02-17 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途 |
CN104610257B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 |
CN104610260B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
CN104592227B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途 |
CN104610258B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途 |
CN104672236B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途 |
CN104557929B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
CN104557927B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
CN104650082B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类凝血因子Xa抑制剂、制备方法及其用途 |
CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
CN104557930B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 |
CN104610259B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
CN104650081B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 凝血因子Xa抑制剂、制备方法及其用途 |
MX2017014287A (es) | 2015-05-11 | 2018-03-07 | Basf Se | Proceso para preparar 4-amino-piridazinas. |
JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
WO2017069173A1 (ja) * | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
CN110054619A (zh) * | 2018-01-18 | 2019-07-26 | 西北农林科技大学 | 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂 |
CA3096497A1 (en) | 2018-04-10 | 2019-10-17 | Bayer Aktiengesellschaft | Oxadiazoline derivatives |
CN109991355B (zh) * | 2019-04-12 | 2021-05-11 | 中国烟草总公司郑州烟草研究院 | 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法 |
WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ262664A (en) * | 1993-02-22 | 1997-04-24 | Merck & Co Inc | Heterocyclic substituted derivatives, and medicaments thereof |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
UA56197C2 (uk) * | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
EP0975625A1 (en) * | 1997-04-14 | 2000-02-02 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
CA2318351A1 (en) * | 1997-12-26 | 1999-07-08 | Hidemitsu Nishida | Aromatic compounds having cyclic amino or salts thereof |
CN1291892A (zh) * | 1998-01-27 | 2001-04-18 | 阿温蒂斯药物制品公司 | 取代的氧代氮杂杂环基因子Xa抑制剂 |
JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
CA2317017A1 (en) * | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
JP2003529531A (ja) * | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルXa因子阻害剤 |
-
2000
- 2000-07-26 JP JP2001512520A patent/JP4829449B2/ja not_active Expired - Fee Related
- 2000-07-26 IL IL14749500A patent/IL147495A0/xx active IP Right Grant
- 2000-07-26 TR TR2002/00225T patent/TR200200225T2/xx unknown
- 2000-07-26 PL PL00354998A patent/PL354998A1/xx not_active Application Discontinuation
- 2000-07-26 CZ CZ2002323A patent/CZ2002323A3/cs unknown
- 2000-07-26 DE DE60041584T patent/DE60041584D1/de not_active Expired - Lifetime
- 2000-07-26 EP EP00951781A patent/EP1208097B1/en not_active Expired - Lifetime
- 2000-07-26 AT AT00951781T patent/ATE423113T1/de not_active IP Right Cessation
- 2000-07-26 WO PCT/IB2000/001156 patent/WO2001007436A2/en active Search and Examination
- 2000-07-26 AU AU64628/00A patent/AU773227B2/en not_active Ceased
- 2000-07-26 CA CA002382755A patent/CA2382755A1/en not_active Abandoned
- 2000-07-26 SK SK118-2002A patent/SK1182002A3/sk unknown
- 2000-07-26 CN CN00810877A patent/CN1420882A/zh active Pending
- 2000-07-26 HU HU0203375A patent/HUP0203375A3/hu unknown
- 2000-07-26 EE EEP200200045A patent/EE200200045A/xx unknown
- 2000-07-26 BR BR0013179-2A patent/BR0013179A/pt not_active IP Right Cessation
- 2000-07-26 MX MXPA02000888A patent/MXPA02000888A/es active IP Right Grant
- 2000-07-26 KR KR1020027001192A patent/KR20020087041A/ko not_active Application Discontinuation
- 2000-07-26 RU RU2002105011/04A patent/RU2002105011A/ru unknown
-
2002
- 2002-01-06 IL IL147495A patent/IL147495A/en not_active IP Right Cessation
- 2002-01-15 NO NO20020214A patent/NO20020214L/no not_active Application Discontinuation
- 2002-01-22 ZA ZA200200543A patent/ZA200200543B/en unknown
- 2002-01-22 BG BG106340A patent/BG106340A/xx unknown
- 2002-01-25 HR HR20020076A patent/HRP20020076A2/hr not_active Application Discontinuation
- 2002-01-25 CR CR6563A patent/CR6563A/es unknown
-
2003
- 2003-09-09 HK HK03106404.4A patent/HK1054227A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20020214L (no) | 2002-04-02 |
IL147495A0 (en) | 2002-08-14 |
RU2002105011A (ru) | 2004-01-20 |
JP4829449B2 (ja) | 2011-12-07 |
CZ2002323A3 (cs) | 2002-05-15 |
PL354998A1 (en) | 2004-03-22 |
JP2003508353A (ja) | 2003-03-04 |
BR0013179A (pt) | 2002-04-02 |
BG106340A (en) | 2002-10-31 |
ATE423113T1 (de) | 2009-03-15 |
CR6563A (es) | 2008-11-25 |
EE200200045A (et) | 2003-06-16 |
WO2001007436A2 (en) | 2001-02-01 |
HK1054227A1 (zh) | 2003-11-21 |
SK1182002A3 (en) | 2002-11-06 |
CA2382755A1 (en) | 2001-02-01 |
HRP20020076A2 (en) | 2003-12-31 |
HUP0203375A3 (en) | 2005-03-29 |
EP1208097A2 (en) | 2002-05-29 |
CN1420882A (zh) | 2003-05-28 |
EP1208097B1 (en) | 2009-02-18 |
WO2001007436A3 (en) | 2001-08-23 |
KR20020087041A (ko) | 2002-11-21 |
IL147495A (en) | 2007-07-24 |
DE60041584D1 (de) | 2009-04-02 |
HUP0203375A2 (hu) | 2002-12-28 |
AU773227B2 (en) | 2004-05-20 |
ZA200200543B (en) | 2003-08-27 |
AU6462800A (en) | 2001-02-13 |
TR200200225T2 (tr) | 2002-06-21 |
MXPA02000888A (es) | 2002-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20020214L (no) | Substituerte oksoazaheterocyklylforbindelser | |
AP2000001889A0 (en) | Substituted ozoazaheterocyclyl factor Xa inhibitors. | |
ATE297203T1 (de) | Antithrombotische mitteln | |
ATE272633T1 (de) | Aromatische amiden | |
DE69831868D1 (en) | Antithrombosemittel | |
DE69931393D1 (de) | Antithrombotische amide | |
ATE374765T1 (de) | Substituierte heterocyclische amide | |
WO2001019828A3 (en) | Kinase inhibitors as therapeutic agents | |
MXPA04001323A (es) | Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso. | |
CY1107634T1 (el) | Φαρμακευτικη συνθεση | |
DK1140918T3 (da) | Thrombininhibitorer | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
BR0313969A (pt) | Inibidores de oxitocina | |
SE9901077D0 (sv) | Novel use | |
ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
DE60114640D1 (en) | Antithrombosemittel | |
RS79703A (en) | Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors | |
DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien | |
MXPA03002493A (es) | Proceso eficiente para preparacion de un inhibidor del factor xa. | |
ATE372982T1 (de) | 2-(3-sulfonylamino-2-oxopyrrolidin-1- yl)propanamide als factor xa inhibitoren | |
EA200401099A1 (ru) | Производные гетероциклического амида | |
ATE382607T1 (de) | Antitrombotische aether | |
NO981089L (no) | Epoksy-azetidinoner, fremstilling og anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |